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Abstract
Background: Praziquantel (PZQ) is the only widely available drug to treat schistosomiasis. Given the potential for drug
resistance, it is prudent to search for novel therapeutics. Identification of anti-schistosomal chemicals has traditionally relied
on phenotypic (whole organism) screening with adult worms in vitro and/or animal models of disease—tools that limit
automation and throughput with modern microtiter plate-formatted compound libraries.
Methods: A partially automated, three-component phenotypic screen workflow is presented that utilizes at its apex the
schistosomular stage of the parasite adapted to a 96-well plate format with a throughput of 640 compounds per month.
Hits that arise are subsequently screened in vitro against adult parasites and finally for efficacy in a murine model of disease.
Two GO/NO GO criteria filters in the workflow prioritize hit compounds for tests in the animal disease model in accordance
with a target drug profile that demands short-course oral therapy. The screen workflow was inaugurated with 2,160
chemically diverse natural and synthetic compounds, of which 821 are drugs already approved for human use. This affords a
unique starting point to ‘reposition’ (re-profile) drugs as anti-schistosomals with potential savings in development timelines
and costs.
Findings: Multiple and dynamic phenotypes could be categorized for schistosomula and adults in vitro, and a diverse set of
‘hit’ drugs and chemistries were identified, including anti-schistosomals, anthelmintics, antibiotics, and neuromodulators. Of
those hits prioritized for tests in the animal disease model, a number of leads were identified, one of which compares
reasonably well with PZQ in significantly decreasing worm and egg burdens, and disease-associated pathology. Data arising
from the three components of the screen are posted online as a community resource.
Conclusions: To accelerate the identification of novel anti-schistosomals, we have developed a partially automated screen
workflow that interfaces schistosomula with microtiter plate-formatted compound libraries. The workflow has identified
various compounds and drugs as hits in vitro and leads, with the prescribed oral efficacy, in vivo. Efforts to improve
throughput, automation, and rigor of the screening workflow are ongoing.
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Introduction
Treatment and control of the flatworm disease, schistosomiasis,
relies on a single drug, praziquantel (PZQ). Since the first clinical
trials in the late 1970’s [1], PZQ has proven safe and effective
against all three major forms of the disease, and today, declining
costs make the drug more affordable, currently at around 7–19 US
cents per 600 mg tablet [2]. A single oral dose of 40–60 mg/kg is
sufficient to achieve cure rates of 60–90% [3] while facilitating
patient compliance, especially among children. Clinically relevant
and widespread resistance, despite occasional and isolated inci-
dences [4], has yet to occur. This fortuitous situation stands in
contrast to the situation for some other ‘neglected tropical diseases’,
(NTDs; [5]) for which antiquated and often toxic drugs must be
parenterally administered over a number of days or weeks and
which increasingly have problems associated with drug resistance
[6]. Thankfully, concerted pharmaceutical discovery efforts via
‘public-private partnership’ (PPP) consortia [7,8] are ongoing to
address this desperate situation and robust ‘drug pipelines’ have
been established which, hopefully, should yield new therapies over
the next ten to 15 years. All of this recent activity has bypassed
schistosomiasis, due in part to the tremendous success of PZQ.
www.plosntds.org 1 July 2009 | Volume 3 | Issue 7 | e478Yet, reliance on a single drug to treat a population of over 200
million people infected and over 700 million people at risk over
three continents [9] seems particularly perilous when considering
the threat of drug resistance. Also, PZQ is not without problems.
Principal among these is its relative inactivity against migratory
juvenile and sub-adult worms [10,11] meaning that, for effective
treatment and sustainable control, PZQ must be given on a
regular basis. Thus, recent discussions, as part of treatment
landscape for human helminthiases in general [12], have focused
on reawakening the need to search for alternatives to PZQ,
including the development of combinations of drugs incorporating
PZQ [13,14]. The latter option, if more difficult and costly to
develop, has the longer term benefit of extending the availability of
PZQ while hindering the onset of resistance to this most valuable
of drugs.
Only to a limited extent has the underlying rationale for inquiry
of anti-schistosomal compounds (and anthelmintics in general)
involved detailed knowledge of the molecular drug target or
mechanism of action although there are some notable advances,
e.g., inhibition of redox [15] and proteolytic enzymes [16], and
heme aggregation [17]. The relative lack of validated molecular
drug targets for this parasite is in stark contrast to those
underpinning entire drug development portfolios of PPPs tackling
other infectious diseases of global import such as malaria and the
trypanosomiases [7,8]. Hopefully, this paucity of targets can be
better addressed with the recent availability of the draft genomes
of both Schistosoma mansoni [18] and S. japonicum, and the first
attempts to prioritize those targets ([19]; TDR Drug Targets
Prioritization Database [20]). More common in schistosome drug
discovery has been the complementary approach of phenotypic
(whole organism) screening in vitro (usually with adult worms) and/
or animal models of disease to measure compound efficacy [21].
These strategies are usually without specific knowledge of the
target and/or mechanism of action (e.g., [22,23]), or for which
bioactivity has been characterized in other parasitological or
biomedical settings [24,25,26]. They are of proven value. For
example, PZQ was first developed as a veterinary cestocide before
being tested in an animal model of schistosomiasis [27] and long
before data regarding its mechanism of action was gathered.
However, the pace of discovery with these techniques is somewhat
slow, relying on a small number of research groups expert in
handling the complex schistosome life cycle and working with both
finite yields of parasite (adult parasites must be harvested from
mammalian hosts) and long screen timelines (it takes approxi-
mately 30 days for S. mansoni infections to become patent in the
mouse model [28]).
Here, we have taken an alternative approach to phenotypic
screening by designing a three-component screen workflow built
upon juvenile parasites (schistosomula) that are easily obtainable
from the vector snails and in far greater numbers than adult
parasites. The screen is formatted to 96-well microtiter plates thus
providing increased throughput and improved interfacing with
similarly formatted small molecule libraries maintained in-house at
the UCSF Small Molecule Discovery Center (SMDC; http://
smdc.ucsf.edu/). Adult parasite screens in vitro form the second
component of the workflow that is completed with compound
efficacy tests in a murine model of patent schistosomiasis. Two
GO/NO GO filter points are strategically placed in the screen
workflow to prioritize compounds more likely to meet the target
product profile (TPP) for treatment of schistosomiasis and its
demand for short course oral chemotherapy [29]. As constructed,
the entire process is intended to streamline and accelerate the
identification of hit compounds and chemistries in vitro, and leads
in vivo.
The screen workflow was inaugurated using a library of
commercially available and chemically diverse compounds.
Approximately 41% of the library comprises drugs already
approved for human use thereby opening the possibility for
repositioning (re-profiling or re-purposing) [30] chemical entities
as novel anti-schistosomals. The same collections have already
provided a number of leads against other parasites [31,32,33].
Drug repositioning offers shortened development timelines and
decreased risk with compounds having already passed regulatory
clinical trials with full toxicological and pharmacokinetic profiles
[7,30]. All of this adds to up to significant potential cost savings –
important in the context of diseases afflicting the poor for which
investment returns will be marginal. The results accrued from the
inaugural screen are promising in that a number of potent anti-
schistosomal single compounds and chemical classes have been
identified in vitro, some of which elicit demonstrable anti-
schistosomal effects in the murine model of disease. Importantly,
these and future data arising from the screen workflow are made
public via various online portals to allow those interested examine
and mine the outputs and, hopefully, identify their own
opportunities for NTD drug development.
Methods
Maintenance of the S. mansoni life cycle
A Puerto Rican isolate is maintained in the laboratory using the
intermediate snail host, Biomphalaria glabrata and the Golden Syrian
hamster Mesocricetus auratus (5–6 weeks old; Simonsen labs) as the
definitive host. Animals were maintained and experiments carried
out in accordance with protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at UCSF. Infections
with S. mansoni are initiated by subcutaneous injections of 800–
1000 cercariae. At 6–7 weeks post-infection (p.i.), hamsters are
euthanized with peritoneal (i.p.) injections of 50 mg/kg sodium
pentobarbital and adult worms harvested by reverse perfusion of
Author Summary
The flatworm disease schistosomiasis infects over 200
million people with just one drug (praziquantel) avail-
able—a concern should drug resistance develop. Present
drug discovery approaches for schistosomiasis are slow
and not conducive to automation in a high-throughput
format. Therefore, we designed a three-component screen
workflow that positions the larval (schistosomulum) stage
of S. mansoni at its apex followed by screens of adults in
culture and, finally, efficacy tests in infected mice.
Schistosomula are small enough and available in sufficient
numbers to interface with automated liquid handling
systems and prosecute thousands of compounds in short
time frames. We inaugurated the workflow with a 2,160
compound library that includes known drugs in order to
cost effectively ‘re-position’ drugs as new therapies for
schistosomiasis and/or identify compounds that could be
modified to that end. We identify a variety of ‘hit’
compounds (antibiotics, psychoactives, antiparasitics,
etc.) that produce behavioral responses (phenotypes) in
schistosomula and adults. Tests in infected mice of the
most promising hits identified a number of ‘leads,’ one of
which compares reasonably well with praziquantel in
killing worms, decreasing egg production by the parasite,
and ameliorating disease pathology. Efforts continue to
more fully automate the workflow. All screen data are
posted online as a drug discovery resource.
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Carlsbad, CA).
Preparation of schistosomula and adult parasites for the
screen workflow
Upon exposure to light, 50–100 snails that are patent with S.
mansoni infection, are induced to shed cercariae into the
surrounding water. Cercariae are cleaned and concentrated over
a series of sieves using distilled water and allowed to stand on ice in
a 50 mL polystyrene tube for 1 h. During this time, cercariae
clump, settle to the bottom and stick to the inside surface of the
tube. The water is poured off and replaced with 9 mL ice-cold
‘Incomplete’ Medium 169 ([35]; custom made at the UCSF Cell
Culture Facility) that contains 16penicillin-streptomycin solution.
Cercariae are mechanically transformed into schistosomula by
passing back and forth between two 10 mL syringes attached via a
22-gauge double-headed needle (adapted from [36]). After
deposition into a 9 cm diameter Petri dish, cercarial heads are
separated from tails by swirling in Incomplete Medium 169 and
the lighter tails aspirated leaving the heads (schistosomula) settled
in the center of the dish. Under sterile conditions, schistosomula
are washed 3 times in Incomplete Medium 169 and allowed to
settle over ice in a 1.5 mL microfuge tube. Parasites are kept on ice
for up to 2 h prior to screening with compounds. As a note,
Medium 169 is preferred over RPMI as a culture medium for
schistosomula – worms survive with ,10% mortality for up to 4
weeks whereas in RPMI, approximately 40–60% of the parasites
die within 3 days with continued mortality out to two weeks
(Ruelas and Caffrey, unpublished).
Adult worms, perfused from hamsters, are washed 5 times in
RPMI 1640 containing 16 penicillin-streptomycin solution and
10 mg/mL amphotericin B (both supplied by the UCSF cell
culture facility). After 3 further washes in Incomplete Medium
169, parasites are maintained in ‘Complete’ Medium 169 (with the
addition of 10% fetal bovine serum (FBS; HyClone, Logan, Utah)
at 37uC and 5% CO2 for up to 24 h prior to screening with
compounds.
Compound storage and handling for the schistosomula
component of the screen workflow
The ‘Spectrum’ and ‘Killer’ compound collections, together
comprising 2,160 (1,992 unique) compounds were purchased from
Microsource Discovery Systems, Inc. (Gaylordsville, CT, USA;
http://www.msdiscovery.com/). Information on both is available
for download as .xls files from http://www.msdiscovery.com/
spectrum.html and http://www.msdiscovery.com/killer.html, re-
spectively. Together the library contains synthetic compounds,
natural products and drugs of which 821 are FDA-approved [31].
The library is maintained as 1 and 5 mM stocks in 384-well plates
and 280 C at the UCSF Small Molecule Discovery Center that is
juxtaposed to the UCSF Sandler Center.
For the first component of the screen workflow (see Figure 1 for
schematic) involving primary screens of schistosomula, 96-well
polystyrene dilution plates (Corning, MA) are prepared using a
Matrix WellMate bulk dispenser and a Biomek FX
p liquid
handling system. To these plates, the FX
p transfers 4 mLo f
1 mM compound in neat DMSO from quadrants of the 384 well
stock plates. Eighty compounds from each quadrant are
transferred to each dilution plate leaving the outer two columns
empty. The WellMate then dispenses 16 mL DMSO and 180 mL
Incomplete Medium 169 to the dilution plates to yield 20 mM
compound in 200 mL 10% DMSO. Finally, the FX
p transfers
10 mL of diluted compounds to the 96-well screen plates followed
by 180 mL of Complete Medium 169. Under sterile conditions,
10 mL of schistosomula (200–300 worms) maintained on ice are
added manually so that the final concentrations of test compound
and DMSO per well are 1 mM and 0.5%, respectively. The outer
two columns (1 and 12) of each screen plate are kept empty for
eventual manual addition of the anti-schistosomal compounds,
PZQ and the cysteine protease inhibitor, K777 [16], each at 1 and
5 mM. Plates are maintained at 37uC in a 5% CO2 atmosphere.
For confirmatory screens of schistosomula (Figure 1), consensus
hits (details below) from the primary screen are ‘cherry picked’
using the Matrix WellMate and Biomek FX
p. A custom protocol
in Pipeline Pilot software (Accelrys, CA) generates an Excel file
that is read by the FX
p. This file is designed to randomly distribute
hit compounds among wells containing only DMSO (‘dummy
wells’) in the dilution plate. To start the liquid-handling procedure,
the WellMate transfers 48 mL of neat DMSO into the inner 80
wells of 96-well polystyrene dilution plates. From 5 mM stocks in
neat DMSO, the Span 8 arm on the FX
p then transfers 2 mLo f
consensus hit compounds (or DMSO from a plate containing
100% DMSO) into the dilution plates. To complete the dilution
plates, 150 mL of Incomplete Medium 169 are added to each well.
From this dilution plate, 4 mL are transferred into the 96-well
screen plates followed by 186 mL of Complete Medium 169.
Under sterile conditions, 10 mL schistosomula (200–300) are then
added manually to yield final concentrations of 1 mM and 0.5%
for test compound and DMSO, respectively.
Compound handling for the adult component of the
screen workflow
For the second component of the screen workflow involving
screening of adult S. mansoni (Figure 1), the FX
p Span 8 transfers
4 mL 5 mM hit compounds in neat DMSO into 96-well
polystyrene dilution plates. The hits are distributed randomly in
the first few rows of these plates, but with fewer dummy DMSO
wells to accommodate the smaller 24-well screen plates. Then,
96 mL of neat DMSO are added to this plate using the WellMate
bulk dispenser. From this, 10 mL of the diluted compounds are
added manually to the 24-well screen plates and immediately
mixed with 0.99 mL of Complete Medium 169 to prevent
evaporation of DMSO. Under sterile conditions, adult worms
(4–8 pairs) are manually added in 1 mL Complete Medium 169.
Final concentrations of test compound and DMSO are 1 mM and
0.5%, respectively.
Phenotype scoring and compound concentration
Two screen analysts spent approximately four weeks testing the
Microsource ‘Killer Collection’ with both schistosomula and adult
parasites in order to familiarize themselves with the types of
phenotypes arising and their changes as a function of time.
Phenotypes were scored using a Zeiss Axiovert 40 C inverted
microscope and 610 and 62.5 objective lens for schistosomula
and adults, respectively.
Screening analysts are blind to the compound identities which
are not disclosed until the conclusion of each of the schistosomular
and adult components of the workflow. As a further precaution
against subjective bias, each screen analyst visually scores and
characterizes phenotype ‘hits’ in isolation. Both analysts then
compile ‘consensus hits’. In those cases for which a consensus
cannot be reached the compounds in question are scheduled for
re-screening. With repetition, the failure rate to identify consensus
hits was decreased to less than 5% per plate for both the
schistosomula and adult components of the workflow.
It was also during the four week training period that a decision
was reached on the compound concentration at which the
Schistosome Phenotypic Screen: Hits and Leads
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Killer collection at 10 and 5 mM with schistosomula yielded too
many hits (average of 25 and 15% of the 80 compounds per plate,
respectively) to subsequently perform, in a reasonable time-frame,
in vitro screening with the more limiting adult parasites. At 1 mM,
however, an average 10% hit rate was achieved.
For primary screens of schistosomula, phenotypes were
monitored after 7 d a time frame considered long enough to
record the development of any potentially relevant phenotype
(Figure 1). For confirmatory screens with schistosomules, pheno-
types were scored after 24 h and 7 days in order to identity fast-
acting compounds and re-confirm the data from the primary
screen, respectively. For adult screens, phenotypes were monitored
after 7 and 24 h, and, thereafter, daily up to 4 days (Figure 1).
GO/NO GO filters in the screen workflow
Two GO/NO GO filters are positioned in the screen workflow
in order to prioritize which compounds go forward (Figure 1)
based upon the TPP for schistosomiasis treatment and its demand
for short course oral therapy [29].
The first filter, placed between the schistosomular and adult
components of the workflow, prioritizes compounds yielding
phenotypes by 24 h and removes compounds (where data are
available) that are clearly toxic and/or unsuitable for oral
administration. The second GO/NO-GO filter, upon completion
of the adult screen component, prioritizes those hit compounds for
tests in the murine model of schistosomiasis mansoni. This
prioritization is more complex than the first filter as a number
of parameters must be simultaneously considered. Primary
emphasis is placed on the time to appearance of the phenotype
plus the severity of that phenotype, e.g., fast-acting ‘death’
phenotypes (,24 h) are most preferred. Other factors influencing
the decision include clinical indication (if known) for the
compound including undesirable side-effects (e.g., hormones
disallowed; psychoactives less preferred); oral bioavailability
(preferred over other routes of administration) and data on acute
toxicity (e.g., LD50 oral (p.o.), i.p., and/or intra-venous (i.v.)).
Finally, where compounds with similar chemistries are represented
more than once, a single example is initially considered for tests in
the mouse model.
Figure 1. Workflow for phenotypic screening of S. mansoni. The workflow was prosecuted with the Microsource Discovery Inc.’s ‘‘Spectrum’’
and ‘‘Killer’’ collections that together comprise 2,160 (1,992 unique) compounds, including 821 drugs approved for use with humans (http://www.
msdiscovery.com/). The goal was to interface this parasite with the 96-well plate-formatted small molecule libraries available at the UCSF Small
Molecule Discovery Center (SMDC; http://smdc.ucsf.edu/) and common elsewhere, thereby accelerating throughput and facilitating screen
automation. Schistosomula are placed at the apex of a three-component workflow that subsequently incorporates screens against adult parasites in
vitro and finally an animal model of infection to measure in vivo efficacy. Times at which phenotypes were recorded in vitro are indicated in hours and
days Two GO/NO GO workflow filters allow for prioritization of the ‘hit’ compounds in vitro. The numbers of ‘hits’ generated at various points in the
workflow are indicated in bold typeface. Data arising from each of the three screening components are posted online as a flat file at The Sandler
Center’s ‘Low Hanging Fruit’’ website (http://pathology.ucsf.edu/mckerrow//fruit.html), and in a cross-searchable format, at the database maintained
by Collaborative Drug Discovery (CDD Inc.; (http://www.collaborativedrug.com/). For smaller numbers of compounds, the workflow need not be
hierarchically prosecuted, rather every compound can be screened against both schistosomula and adults.
doi:10.1371/journal.pntd.0000478.g001
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The third and final component of the S. mansoni screen workflow
(Figure 1) entails infections of 4–6 week-old Swiss Webster mice
(Simonsen Laboratories) with S. mansoni that are initiated by
subcutaneous injection of 140 cercariae. Experiments were carried
out in accordance with protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at UCSF. Groups of 4
or 5 mice are used per treatment. Commencing on day 42 p.i.
when S. mansoni infections are patent (i.e., when parasite eggs are
present in feces) compound is administered once daily (QD) and/
or twice daily (BID) for 4 days. This time period is considered
sufficient to record any compound efficacy given that the desired
TPP for any new-anti-schistosomal calls for short course therapy
[15,29]. Compound is administered p.o. (vehicle is 2.5%
Cremophor EL unless otherwise stated) or, i.p., when data on
oral bioavailability are not to hand. The amount of compound to
administer is guided by available LD50 values for acute toxicity, in
which case compound is given close to that value in order to
determine whether a therapeutic window exists. Overt toxicity of
compounds (e.g., death and behavioral changes) is assessed daily
during and after treatment until the time of euthanasia. At 55 days
p.i., mice are euthanized with an i.p. injection of 0.05 mg/g
sodium pentobarbital, and adult worms perfused as described
above for hamsters.
Compound efficacy in vivo is measured as described [16] using a
number of criteria and is compared to that of the anti-schistosomal
drug, PZQ, as a ‘gold standard.’ The criteria include the
parasitological parameters of numbers of male and female worms
recovered by perfusion, and hepatic egg burdens. Also, the
amelioration of pathology as evidenced by decreased liver and
spleen weights is recorded. Attention is also paid to worm size
upon recovery. To recover eggs trapped in liver, whole livers (or
the caudate liver lobe, see below) from individual mice are excised,
weighed and digested in 0.7% porcine trypsin in PBS for 1 h at
37uC on an orbital shaker. Eggs are sedimented at 4uC and
counted under a dissecting microscope as described previously
[37].
Statistics
Data for worm and hepatic egg counts, and organ weights, were
compiled on a per mouse basis and median values calculated per
treatment group. All data were subjected to the Mann-Whitney
nonparametric test to determine any statistical differences in egg
and worm burdens, and organ pathologies between treated and
untreated control mice. As an expedient alternative in some
experiments, particularly in those cases where worm burdens were
not dramatically decreased, hepatic egg counts were calculated as
an average per treatment group rather than per mouse. To do this,
the caudate liver lobe from individual mice was excised, pooled
per treatment group and weighed prior to trypsin digestion and
counting of eggs. The single value arising was then calculated with
respect to the total liver weight in the group and then divided by
the number of mice in the group.
Results
Phenotype classification for schistosomula
During initial testing of the Microsource ‘Killer Collection’, it
became clear that schistosomula display different and often
multiple phenotypes that change over time. Eventually, we could
consistently ascribe six phenotypes to worms under chemical insult
relative to control worms exposed to 0.5% DMSO (Figure 2;
Table S1). The phenotype terms we employed range from the
obvious (‘dead’, ‘overactive’, and ‘rounded’) to the more sublime
(‘dark’, ‘slow’), yet, nonetheless, clearly distinguishable from
DMSO controls. An example of the overactive phenotype is
shown in Video S1 which should be compared with normal worm
movement displayed in Video S2. The last phenotype, ‘degenerate
but mobile’, describes those cases in which the worms are clearly
motile yet severely disrupted in morphology. An example of this
phenotype is produced by PZQ, used as a ‘gold standard’
schistosomicide throughout the screen workflow. PZQ initially
elicited an overactive phenotype (observed within 10 mins) that
progressed to a combination of ‘overactive/degenerate but mobile’
by 7 days (Figure 2C). In contrast, the cysteine protease inhibitor,
K777 [16], also used as a standard compound, had a more
progressive effect; ‘‘slow/dark’’ by 3 days leading to ‘dark/slow/
dead’ by 7 days (Figure 2B).
Phenotype classification for adult worms
Similar to schistosomula, adult worms could manifest multiple
and changing phenotypes in response to chemical insult (Figure 3;
Table S2). There was some overlap in the phenotypes classified
compared to schistosomula: ‘dead’, ‘dark’, ‘slow’ and ‘overactive’
remained relevant whereas ‘rounded’ and ‘degenerate but mobile’
Figure 2. Examples of the different and multiple phenotypes manifest by schistosomula exposed to chemical insult. Worms were
exposed for 7 days to 1 mM of either the schistosomicidal cysteine protease inhibitor, K777 (B), or the current chemotherapy, PZQ (C), and compared
to controls with DMSO alone (A). Phenotypes ascribed are ‘dark/dead’ for K777 and ‘overactive/degenerated but mobile’ for PZQ. Images were
captured using a Zeiss Axiovert 40 C inverted microscope (106 objective) and a Zeiss AxioCam MRc digital camera controlled by AxioVision 40
version 4.5.0.0 software. Scale bar=0.2 mm.
doi:10.1371/journal.pntd.0000478.g002
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blebbing’ (teg. bleb.) to document damage to the surface
(tegument) of the adult; ‘sexes separated’ (sex sep.), whereby the
male and female worms become unpaired, and the self-evident
‘shrunken.’ For example, PZQ, elicited ‘shrunken/dark/slow’
phenotypes (observed within 2 min of addition of 1 mM PZQ) that
progressed to ‘shrunken/dark/sexes sep/teg. bleb/dead’, by 4
days (Figure 3C). In contrast, K777 had a more progressive effect;
‘slow/dark’ by 2 days leading to ‘dark/slow/sexes sep/on sides/
dead’ by 4 days (Figure 3B).
Schistosomula primary and confirmatory screens
Of the 1,992 unique compounds comprising the Microsource
Spectrum and Killer collections, 118 yielded phenotypes (termed
‘hits’ representing 5.9% of the total) in the schistosomula
primary screen component of the workflow after 7 days at a
concentration of 1 mM. The compound names, structures,
therapeutic uses and phenotypes identified are listed in Table
S1. The majority of these (105) were returned as hits in the
confirmatory schistosomula screen component after 7 days and,
of these, 61 (3.1% of all the compounds screened), were fast-
acting, i.e., phenotypes were recorded at the 24 h time-point
(Table S1).
When the Microsource Spectrum and Killer collections are
broken down into their component drug classes (Table 1, Table
S3), and using the 7 d confirmatory screen data, the greatest
percentage of hits per class, as might be expected, was for the
anthelmintics (29%). Within this group the known anti-schistoso-
mals PZQ and hycanthone were identified, as were other
anthelmintics such as niclosamide, bithionol and pyrvinium
pamoate (Table S3). Examples of other drug classes returning
percentage hits greater than 10% are the antibiotics, fungicides,
antineoplastics, dopaminergics and seratonergics.
Upon completion of the first (schistosomular) component of
the screen workflow and bearing in mind the target drug profile
for schistosomiasis [29], the first of two GO/NO-GO filters was
enacted (Figure 1; Table S1). Fast-acting compounds (pheno-
types by 24 h) were prioritized and those clearly toxic or
otherwise inappropriate for oral use were removed. Accordingly,
all but four (phenylmercuric acetate, thimerosal, benzalkonium
chloride and homidium bromide) of the 61 fast-acting
compounds were prioritized for in vitro tests against adult
parasites
Apparent structure activity relationship (SAR) for tricyclic
psychoactive drugs inducing an ‘overactive’ phenotype
in schistosomula
During the first component of the screen workflow it became
clear that certain tricyclic psychoactive compounds within the
Microsource collections, notably the phenothiazines and dibenza-
zepines, elicited a striking ‘‘overactive’’ phenotype that lasted for
the 7 day duration of the experiment. To verify the result, a mini-
screen incorporating the tricyclic psychoactives and structurally
related compounds was set up over three logs of concentration;
1.0, 0.1 and 0.01 mM (Table S4). The overactive phenotype was
confirmed at 1.0 mM for the same compounds and extended to
0.1 mM, but not 0.01 mM. Examination of structural-activity
relationships (SAR) in the phenothiazine and dibenzazepine
classes indicated the importance of an unsubstituted propyl side
chain possessing a terminal dimethylamine function (Figure 4;
Table S4). Even subtle alteration of this pharmacophore, such as
the introduction of a branching methyl substituent, led to
abrogation of the phenotype (compare promazine and trimepra-
zine in Table S4). More dramatic modification of the side chain
(e.g., shortening, introduction of terminal piperazine or piperidine
moieties) similarly abrogated the overactive phenotype. The trend
held whether carbon was substituted for nitrogen at position 10 of
the phenothiazine (or at position 11 of the dibenzazepine) or
whether the tricyclic core was altered internally or substituted.
Adult screen
Of the 57 compounds passing the first GO/NO GO filter and
pursued in the second (adult) component of the screen workflow,
30 were hits (1.5% of the 1,992 compound total) after the maximal
screen time of 4 days at 1 mM (Table S2). Seventeen and 10
compounds generated phenotypes by the 7 h and 24 h time
points, respectively. Included in this set was the antibiotic,
anisomycin, and the anthelmintics PZQ (worms visibly contracted
and shrank within seconds of adding 1 mM), niclosamide,
pyrvinium pamoate and bithionol. Three compounds, including
a former chemotherapy of schistosomiasis, hycanthone, generated
phenotypes after 2 days.
To prioritize candidates for tests in the murine model of
schistosomiasis, a second GO/NO GO filter was implemented
utilizing a greater number of considerations than for the first filter
(Figure 1; Table S2). As for the first filter, due provision was made
for the TPP for schistosomiasis therapy: fast-acting compounds
Figure 3. Examples of the different and multiple phenotypes manifest by adult S. mansoni exposed to chemical insult. Worms were
exposed for 2 days to 1 mM of either K777 (B) or PZQ (C) and compared to controls with DMSO alone (A). Phenotypes ascribed are ‘slow/sex
separated/on sides’ for K777 and ‘slow/dark/shrunken/on sides/sex separated/tegumental blebbing’ for PZQ. Arrows point to female worms. Images
captured using a Zeiss 2000-C Stemi inverted microscope mounted over a Diagnostic Instruments Transmitted Light Base and a Zeiss AxioCam MRc
digital camera controlled by AxioVision 40 version 4.5.0.0 software. Scale bar=0.7 mm.
doi:10.1371/journal.pntd.0000478.g003
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Adrenergic (40) 2 2 1
Analgesic (35) 0 0 0
Anesthetic (17) 1 0 1
Anthelmintic (24) 7 7 5
Antibiotic (178) 20 18 11
Antihistamine (14) 0 0 0
Antihyperlipidemic (16) 2 2 0
Antihypertensive (25) 1 0 1
Antiinflammatory (48) 1 1 1
Antineoplastic (77) 10 10 4
Antioxidant (12) 0 0 0
Antiprotozoal (31) 4 4 2
Antiviral (11) 1 1 0
Cholinergic (64) 4 3 3
Diuretic (18) 0 0 0
Dopaminergic (38) 7 6 5
Estrogen/progesterone (33) 2 1 1
Fungicide (29) 6 5 3
GABAergic (13) 0 0 0
Glucocorticoid (27) 0 0 0
Herbicide (31) 1 1 0
Insecticide (25) 3 2 1
Muscle relaxant (13) 1 1 1
Seratonergic (38) 7 6 6
Other (480) 11 10 4
Unknown (655) 27 25 11
TOTAL (1,992) 118 105 61
See Table S3 for details of the compounds assigned to each drug class.
doi:10.1371/journal.pntd.0000478.t001
Figure 4. SAR for the phenothiazine and dibenzazepine classes of psychoactive drugs eliciting the ‘overactive’ phenotype in
schistosomula. See Table S4 for individual compounds and Supplementary Videos 1 and 2 to compare phenotypes between ‘overactive’ and
control worms.
doi:10.1371/journal.pntd.0000478.g004
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preference now for those that generated the most severe
phenotypes, e.g., ‘‘teg. bleb’’ and ‘‘dead’’. Prioritizations were
counter-balanced by available knowledge of compound efficacy,
toxicity, and side-effects. Thus, bithionol was deprioritized due to
its lack of efficacy in schistosomiasis patients [38] and celastrol due
to its toxicity in mice (death within one day of a single 10 mg/kg
i.p. dose (R. Swenerton, unpublished data). Likewise, rhodomyr-
Figure 5. Structures of compounds prioritized for efficacy tests in the murine model of schistosomiasis mansoni. (A) Hit compounds
arising from the in vitro components of the screen workflow and (B) analogs of niclosamide currently marketed as veterinary anthelmintics or as an
intestinal anti-protozoal in humans (nitazoxanide) and tested in the murine model of schistosomiasis.
doi:10.1371/journal.pntd.0000478.g005
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2 and 20 mM against Hep-G2 (human hepatocellular carcinoma)
and MDA-MB-231 (human mammary adenocarcinoma) cell lines
[39] and was, therefore, not considered further. The tricyclic
psychoactive compounds (e.g., chlorpromazine, imipramine) were
also deprioritized at this stage given that the less severe ‘overactive’
phenotype that appeared by 2 h was either transient (lasting only
until the 24 h time point) or without progression to a more severe
phenotype(s). Also, their psychoactivity and associated side effects,
e.g., sedation, detracted from their immediate consideration. In
all, therefore, five compounds were prioritized for efficacy tests in
the model of murine schistosomiasis: two antibiotics, anisomycin
and lasalocid sodium; two natural products, diffractaic acid and
gambogic acid; and the helminthicide/molluscicide, niclosamide
(Figure 5A, Table S2).
Murine model
For the third and final component of the screen workflow, all
compounds were administered orally in 2.5% Cremophor EL
(unless otherwise stated) either once (QD) and/or twice daily (BID)
for 4 days to mice with patent S. mansoni infections (42 days p.i.).
The antibiotic, anisomycin, at 100 mg/kg p.o. QD, had no
significant effect on male or female worm burdens (Figure 6A), yet
decreased hepatic egg burdens by 36% (calculated as an averaged
single value for the treatment group). Neither liver nor spleen
weights were significantly different from those of the untreated
control group (Figure 6B and C). Increasing to a BID
administration resulted in toxicity; all mice died between 3 and
10 days after the commencement of treatment. The ionophoric
antibiotic, lasalocid sodium, was better tolerated by mice.
Significant decreases in male (44%) and female (41%) worm
counts were measured at 100 mg/kg QD and BID, respectively
(Figure 6A). For egg burdens, reductions of 39 and 55%
(calculated as averaged single values per treatment group) were
measured QD and BID, respectively. Lasalocid sodium also
significantly improved organ pathology compared to controls
(Figure 6B and C).
For the Usnea lichen metabolite, diffractaic acid poor solubility
in aqueous media or vehicle prevented the ability to accurately
gavage mice. Therefore, i.p. administration in 50 mL 100%
DMSO over a range of doses (10, 40 and 100 mg/kg) was
performed to determine compound efficacy while also observing
for overt toxicity. No decrease in worm or egg burdens was
measured at the lower doses, whereas at 100 mg/kg, all mice died
within 7 days of the cessation of treatment (data not shown).
Gambogic acid, a xanthone isolated from various species of the
Garcinia tree, was recently shown to be non-toxic in rats after oral
administration every other day for 13 weeks at 30 and 60 mg/kg
in 2% carboxymethylcellulose-sodium [40]. Using the same
vehicle at 100 mg/kg QD, no effects on worm or egg burdens
were recorded (data not shown).
The final compound, niclosamide (295-dichloro-49-nitrosalicy-
lanilide), a molluscicide and intestinal helminthicide, is poorly
absorbed across the intestinal wall. Therefore, we obtained from
Bayer a wettable powder formulation of the compound (marketed
as Bayluscide WP 70) that is better absorbed (in rats about a third
of an oral dose [41]). However, in tests with both niclosamide
formulations at 100 mg/kg BID, no effects on worm or egg
burdens were noted (data not shown). Further, niclosamide was
ineffective at 100 mg/kg BID in two additional vehicles (2%
Tween80/7% ethanol and 6% PEG 4000/2%Tween 80/7%
ethanol). In a final attempt to demonstrate efficacy, i.p.
administration of niclosamide at 100 mg/kg BID in 100 mL
25% DMSO was without effect – upon dissection of mice the
Figure 6. Effect of lasalocid sodium and anisomycin on male
and female worm burdens, and organ pathology (as measured
by weight) in mice infected with S. mansoni. Compounds were
administered orally QD or BID at the doses indicated for 4 days 42 days
after infection with 140 S. mansoni cercariae. Points represent data from
individual treated or untreated (control) infected mice. The horizontal
bars represent median values. Significance (p) values are indicated
where p#0.05. Egg burdens were calculated as single values per
treatment group (see text for details).
doi:10.1371/journal.pntd.0000478.g006
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on the inner side of peritoneal membrane, indicating that much of
the compound had not been absorbed.
Screening niclosamide analogs in the murine model
Based on the strong in vitro efficacy measured for niclosamide
against both schistosomula (Table S1) and adults (Table S2), and
notwithstanding its lack of in vivo efficacy, we searched for
structurally related compounds that are commercially available
and have demonstrated oral efficacy against helminths or
protozoa. Three salicylanilides, closantel, oxyclozanide, and
rafoxanide, and the nitrothiazolyl-salicylamide, nitazoxanide
(Figure 5B) were purchased. The salicylanilides are well-estab-
lished drugs used in the agribusiness sector as helminthicides,
including against liver fluke disease caused by Fasciola hepatica [42].
They have also displayed variable efficacies in experiments with
farm animals harboring agriculturally important Indian schisto-
some species such as Schistosoma incognitum and Schistosoma nasale
([43,44]). Nitazoxanide (marketed as Alinia) is approved for the
treatment of diarrhea caused by Cryptosporidium parvum and Giardia
lamblia and has shown efficacy against human fascioliasis hepatica
[45]. Accordingly, we judged there to be sufficient precedent and
data available to move these compounds straight into our mouse
disease model. The oral efficacy of these drugs were compared to
the ‘gold standard’ drug, PZQ.
When administered at 100 mg/kg p.o. QD for 4 days
commencing at 42 days p.i., PZQ significantly decreased male
(91%) and female (87%) worm burdens (Figure 7A) and these were
associated with a decreased hepatic egg load (60%; Figure 7B) and
improved organ pathology (Figure 7C and D). The decrease in egg
burden was not considered significant, however, due to the low
load recorded for one of the control mice. The few worms
surviving treatment and recovered by perfusion were the smallest
seen in all of the in vivo experiments and some were physically
damaged (not shown). By comparison, BID administration of the
salicylanilides, closantel and oxyclozanide, at 100 mg/kg yielded
less pronounced effects on worm burdens (only oxyclozanide
significantly decreased female loads by 53%; Figure 7A) and egg
burdens were not affected (Figure 7B). However, worms recovered
after oxyclozanide treatment were smaller than controls (not
shown) and organ pathology (significantly so for the spleen) was
also improved (Figure 7C and D). The third salicylanilide tested,
rafoxanide, at either 100 mg/kg QD or BID, caused mouse
mortality within 5 days of the cessation of treatment, however, this
seemed not to be due to systemic toxicity per se but rather an
accretion of drug in the stomach that caused gastric blockage. At
50 mg/kg QD (i.e., half the dose of PZQ) all mice survived. The
drug was the most effective of the niclosamide analogs tested
significantly decreasing male (56%) and female (50%) worm loads
(Figure 7A). Also, worms recovered were smaller than controls (not
shown). Egg counts were decreased by 49%, but as noted for PZQ
above, the value was not significant due to an outlier control
mouse with a particularly low hepatic egg count. Rafoxanide was
as effective as PZQ in improving organ pathology (Figure 7C and
D). The final niclosamide analog tested, nitazoxanide, was without
effect on worm burdens at 100 mg/kg QD and BID (Figure 8A)
but significantly improved organ pathology BID (Figure 8B and
C). Nitazoxanide also decreased egg outputs by 34% (calculated as
a single averaged value per treatment group).
Discussion
Compared to the high profile activity supporting the develop-
ment of novel anti-protozoal and anti-infective therapies [7,8] the
pace of drug discovery for anti-schistosomals (and anthelmintics
in general) is slow. For schistosomiasis, a number of mutually
suppressive factors are responsible. Perhaps foremost is the
success and clinical reliability of PZQ that have dampened
investment in a dedicated drug development pipeline, a situation
in stark contrast to malaria and protozoal NTDs for which drug
toxicity and/or increasing drug resistance fuel a number of
multinational PPP programs to identify new therapeutics [7].
Other contributing factors are; the relatively small number of
groups involved in anti-schistosomal discovery, the need to
maintain a complex life-cycle that generates finite parasite yields
and the long identification and development time lines
associated with phenotypic (whole organism) screens as tradi-
tionally prosecuted in animal models and/or in vitro with adult
worms. Despite these drawbacks, phenotypic screening has
successfully identified PZQ and other vital anthelmintics (e.g.,
albendazole and ivermectin) that are in medical use today. Most
often, the compounds originated in the animal health sector as
part of its discovery programs to identify veterinary anti-
parasitics [46,47].
For this report, we have designed a phenotypic screen process
by introducing a three-component workflow (Figure 1) that places
S. mansoni schistosomula at its apex. The intent is to streamline and
accelerate the identification of anti-schistosomal compounds by
interfacing the helminth with the microtiter plate (96- and/or 384-
well) formatted compound libraries and associated robotic liquid
handling systems now standard in industry and many academic
institutions, and routinely employed to screen the more tractable
protozoan parasites [7]. Given their small size (,200660 mm)
schistosomula are readily adaptable to the 96-well plate format
and survive for 7 days with less than 10% mortality under the
conditions described. Also, they are quickly and easily transformed
from the invasive cercariae that are harvestable in their tens of
thousands on at least a weekly basis from vector snails. Both points
are immediately attractive and conducive to designing a higher
throughput screen workflow. The alternative adult parasite is too
large for 96-well plate formatting and can only be harvested from
vertebrate hosts (e.g., mice and hamsters) in more limiting
numbers, and entails considerable expenditure associated with
animal procurement and maintenance. That stated, adults are not
omitted entirely from the screening process but are placed
downstream of schistosomula when the number of compounds
to be tested is more manageable – a consideration also of
importance for the final component of the workflow involving the
animal model of schistosomiasis.
The Microsource collections of 2,160 compounds were
prosecuted at a throughput of 640 compounds/month for the
primary schistosomular screen component. With one full-time
technician and an associate analyst it took 20 weeks to complete
the in vitro screening of the collections against schistosomula and
adults. Efforts to at least double the screening capacity of the first
component of the screen workflow are being studied, for example,
through the employment of additional staff and expansion of our
in-house S. mansoni life-cycle. Also, screen formatting to 384-well
plates is being considered together with the complete automation
of both the liquid handling of the parasite and phenotype
identification and categorization. Data accrued from each
component of the screen workflow is available as a flat file online
at the UCSF Sandler Center’s ‘Low Hanging Fruit’ website
http://www.sandler.ucsf.edu/fruit.html and at http://www.colla-
borativedrug.com/, a database that can be mined across
compounds and parasites to identify molecules and chemistries
of interest. Both sites are continually updated as screening
campaigns are concluded and it is hoped that the data will
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NTDs.
The descriptive approach employed here to annotating the
dynamic responses of this metazoan parasite to chemical stimuli
differs necessarily from the single end-point fluorometric or
colorimetric assays, now routine for high-throughput assays of
single-celled organisms and with which a rigorous quantification of
a live versus death ratio is relatively facile [7]. Given the
traditionally slower compound throughput for schistosome screen-
ing, the demand for marker dyes or reagent-based kits has simply
not been present with visual-based scoring systems being the norm
[21,22,23]. Our attempts to incorporate nuclear dyes (e.g.,
propidium iodide and DAPI) as a quantitative marker of cell
death in schistosomula did not correlate with the clear deleterious
action of some compounds observed under bright field microscopy
(Caffrey, unpublished data). Often dyes were simply excluded from
crossing the schistosome tegument regardless of worm condition.
Thus, our decision to visually classify phenotypes, though
potentially prone to subjectivity, turned out to be a consistent
semi-quantitative approach as employed, i.e., using blind consen-
sus determination of bioactivity by trained analysts familiar with
the parasite’s phenotypic manifestations (see discussion below).
Further, it might be argued that the workflow, because of its
simplicity, and without the need for expensive kits or reagents, is
more adaptable to a greater variety of discovery settings.
Nevertheless, we are aware that any attempt to improve the
quantitative rigor of hit identification and classification should be a
primary goal. Accordingly, we are examining a number of
automated time-lapse image capture platforms to improve
efficiency and accuracy, including the ability to record phenotypes
too subtle to be observed with the human eye.
In addition to increased throughput and improved automation,
the logistical decision to commence the screen workflow with the
schistosomulum stage has both potentially advantageous and
disadvantageous consequences. Of advantage is that the workflow
may identify compounds that are active against both immature
and adult stages of parasite, or, at least, against immature
parasites. This is important in the context that the current
chemotherapy, PZQ, is markedly less effective against the
immature (migratory and sub-adult) parasite compared to mature
egg-laying adults [10,11,48]. Thus, the identification and devel-
opment of a small molecule prophylaxis for individuals harboring
immature parasites, such as in areas of higher transmission, would
be of considerable value. By extension, the opportunity to develop
a combination (possibly synergistic) therapy with PZQ to decrease
the threat of resistance to the latter may also be facilitated by the
present screen workflow that commences with the schistosomular
stage rather than adults. The concept of a PZQ-based combina-
tion therapy based on reciprocal drug efficacy against immature
and mature parasites has already shown value with the artemisinin
class of compounds ([14] and references therein).
A possible disadvantage of the current screening approach is the
potential for missing compounds that are inactive against
schistosomula, yet, nevertheless, might have yielded interesting
phenotypes against adults worms. We accept this possibility as part
of the overall goal to streamline and accelerate the identification of
anti-schistosomal compounds. We would emphasize that, where
Figure 7. Effect of closantel, oxyclozanide, rafoxanide and PZQ
on male and female worm burdens, egg burdens and organ
pathology in mice infected with S. mansoni. Compounds were
administered orally for 4 days 42 days after infection with 140 S.
mansoni cercariae. Doses administered were: 100 mg/kg BID for
closantel and oxyclozanide, 50 mg/kg QD for rafoxanide and 100 mg/
kg QD for PZQ. Points represent data from individual treated or
untreated (control) infected mice. The horizontal bars represent median
values. Significance (p) values are indicated where p#0.05.
doi:10.1371/journal.pntd.0000478.g007
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can be conducted in a non-hierarchical manner whereby every
compound is tested against both schistosomula and adults.
Whether a compound is a hit or not or whether it passes or fails
the GO/NO GO criteria as implemented here, all screen data are
made publicly available for (re)interpretation.
As to the choice of compound collections maintained at the
UCSF SMDC (http://smdc.ucsf.edu/) to initiate the screen
workflow, the Microsource Spectrum and Killer collections
seemed appropriate for a number of reasons. First, the collections
comprise a tractable set of 1,992 unique compounds, so that with a
modest throughput the first and second components of the
workflow were complete within 20 weeks. Secondly, the collections
have a track record of yielding novel leads against other parasites
including Plasmodium falciparum [31,33] and Trypanosoma brucei [32].
Finally, the collections contain a chemically diverse set of natural
and synthetic small molecules, 41% (821 compounds) of which are
drugs already FDA-approved. From a drug-repositioning stand-
point, this is particularly attractive because of the existence of
clinical data (e.g., adsorption, distribution, metabolism, excretion
and toxicity (ADMET)) that could contribute to fast-tracking these
compounds as anti-schistosomals, especially as the compounds are
off-patent and without intellectual property concerns.
Of the 118 compounds identified as hits and phenotypically
classified after 7 days of incubation in the primary schistosomular
screen component, 105 were confirmed. Likewise, for the adult
component of the workflow, repeated tests with compounds
resulted, in most cases, in the same phenotypes. Thus, our blinded
consensus approach to visually recording bioactivity provided
reasonable reproducibility. In further support of the strategy,
known schistosomicides, including PZQ and hycanthone, were,
without fail, identified and consistently characterized, as were
other anthelmintics, such as bithionol and niclosamide. Impor-
tantly, direct visual observation allowed us to identify and record
the multiple and changing phenotypes that are possible with
schistosomes and, not least, discover an apparent SAR for tricyclic
psychoactive compounds primarily focused on the structure of the
side chain. As yet the molecular target(s) of the dibenzazepine and
phenothiazine drugs in question is unknown. It is possible that the
‘overactive’ phenotype is not neuroreceptor-mediated but perhaps
a result of membrane interference (depolarization?). Nonetheless,
it is interesting that, over a two log-fold concentration, compounds
designed to interact with different ligand-gated receptors in
humans nevertheless yield the same phenotype in the parasite,
suggesting that a single parasite receptor or a discrete subset of
receptors may be the target. By mining the available genome
sequence information for S. mansoni [18,19], one might envisage
RNA interference of candidate cholinergic, dopaminergic or
seratonergic receptors in an effort to modulate the overactive
phenotype. This would prove the hypothesis that these compounds
share a receptor and aid the development of an SAR-based drug
discovery program.
Both GO/NO GO filters in the workflow were designed in
consideration of the TPP demanded for new anti-schistosomal
drugs that employs the current therapeutic, PZQ, as a gold-
standard. The bar is high - PZQ decreases worm burdens by
between 60 and 90% in a single oral dose [3,48]. Criteria of speed
of appearance, phenotype severity (death preferred) and oral
suitability were balanced with clinical data on dosage and safety.
As interpreted for this report, the second GO/NO GO filter
removed a number of compounds and compound classes that
elicited striking phenotypic effects. Among these were the tricyclic
psychoactive compounds. The ‘overactivity’ they elicited may yet
prove therapeutically significant, perhaps by disrupting the
Figure 8. Effect of nitazoxanide on male and female worm
burdens, and organ pathology in mice infected with S. mansoni.
Compound was administered orally at the doses indicated for 4 days 42
days after infection with 140 S. mansoni cercariae. Points represent data
from individual treated or untreated (control) infected mice. The
horizontal bars represent median values. Significance (p) values are
indicated where p#0.05. Egg burdens were calculated as single values
per treatment group (see text for details).
doi:10.1371/journal.pntd.0000478.g008
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within the host. Targeting neurotransmission (if that indeed is the
mechanism in schistosomes) is a successful chemotherapeutic
strategy for other helminths ([49]). We will examine the efficacy of
these compounds in the murine disease model at low doses either
alone or in combination with PZQ.
As implemented, the second GO/NO GO filter prioritized five
(niclosamide, anisomycin and lasalocid sodium, diffractaic acid
and gambogic acid) of the 30 hit compounds identified in the
second (adult) component of the screen workflow for tests in the
animal model of schistosomiasis. All five quickly kill (within hours)
both schistosomula and adults at 1 mM in culture. Also, LD50
toxicity data are available against which a dosing regimen can be
prepared and four of the five top hits (excepting diffractaic acid)
can be administered orally.
In the murine model of disease, anisomycin and lasalocid
sodium demonstrated varying parasitological efficacies and
amelioration of hepatic and splenic pathology. Though not as
effective as PZQ, we consider the identification of these novel in
vivo anti-schistosomal activities as proof that the screen as
conceptualized (w.r.t. drug-repositioning) and implemented can
identify potentially interesting and chemically diverse compounds.
Such compounds might be employed for therapy as is or as leads
for further derivatization (e.g., anisomycin is chemically relatively
simple) in order to improve bioactivity while reducing toxicity.
The point is further underscored with the niclosamide analogs.
Though niclosamide and its wettable powder formulation were
ineffective in the mouse model of disease, niclosamide’s rapid and
severe in vitro bioactivity encouraged us to search for other
salicylanilide analogs. We identified a number that are well-
established in the veterinary sector and possess better oral
bioavailability with systemic anthelmintic activity, including
against related trematode parasites [42]. The often significant in
vivo efficacy of these drugs in both the parasitological and
pathological parameters measured, particularly with rafoxanide,
encourage further study of the salicylanilides as a source of anti-
schistosomal leads. These investigations are underway.
In conclusion, as a central component in a pre-clinical drug
discovery pipeline for schistosomiasis, we have developed a
partially automated phenotypic screen workflow of increased
throughput. All data arising are posted and updated online and
work continues to improve automation, rigor and throughput. As
currently performed, the workflow has already identified a
diversity of hit compounds and chemistries in vitro, as well as lead
compounds orally bioactive in a short time frame commensurate
with the TPP for chemotherapy of schistosomiasis [29]. Critically,
the drug-repositioning dimension with the availability of clinical
data for many of these hits and leads can be leveraged to optimize
further compound development. Accordingly, screens of other
libraries containing known drugs are ongoing. Given the
possibility of the emergence of resistance to the current PZQ
monotherapy, and because any strategic planning for therapy of
infectious diseases should incorporate provisions for drug combi-
nations, our future studies will focus on the in vivo performance of
the present and future lead compounds, either alone or in
combination, including with PZQ.
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